Sponsored By

NanoVibronix Extends Distribution Agreement with Ultra Pain Products

The updated agreement means UPPI will continue as the exclusive distributor of PainShield and PainShield Plus for the durable medical equipment sector in the US.

Katie Hobbins

August 23, 2023

2 Min Read
PainShield
Image courtesy of Business Wire

NanoVibronix, a company that produces surface acoustic wave (SAW) portable ultrasonic therapeutic devices, has conditionally extended its distribution agreement with Ultra Pain Products (UPPI), specifically for the distribution of the company’s PainShield and PainShield Plus products.

The company’s SAW technology used in the PainShield and PainShield Pro products, as well as its UroShield and WoundShield products, allow for the creation of low-frequency ultrasound waves that can be used for multiple medical applications, including for disrupting biofilms and bacterial colonization, as well as for pain relief. For these purposes, the devices can be administered at home without the assistance of medical professionals.

NanoVibronix originally executed the agreement with UPPI in 2020, and with the extension, will continue to be the exclusive distributor of PainShield and PainShield Plus devices to the “Durable Medical Equipment distribution sector of the healthcare market” in the US. Additionally, the new agreement provides for an immediate re-stocking order and minimum purchase guarantees through the end of this year.

“Since executing the original distribution agreement in 2020, UPPI has grown to be our largest distributor of PainShield and PainShield Plus,” said Brian Murphy, CEO of NanoVibronix. “The team at UPPI understands the importance of providing clinicians and patients with non-narcotic/non-opiate clinically-supported modalities to reduce the economic burden on the healthcare system and limit the amount of lost working days for injured workers, which makes them a valuable channel for our products.”

The company continues to work with the Centers for Medicare and Medicaid Services (CMS) to obtain full reimbursement approval.

“We submitted the final report with our application to CMS in March 2023, and we remain hopeful for a favorable outcome,” Murphy said. “If approved, reimbursements could begin as early as October 1 of this year. The new agreement with UPPI takes into consideration approval from CMS and provides for modifications that consider the opportunities afforded through reimbursement.”

About the Author(s)

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like